Intest Res  
Treatment and outcomes: medical and surgical treatment for intestinal Behçet’s disease
Tadakazu Hisamatsu, Mari Hayashida
The Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan
Correspondence to: Tadakazu Hisamatsu, The Third Department of Internal Medicine, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitakashi, Tokyo 181-8611, Japan. Tel: +81-422-47-5511 (ext. 5729), Fax: +81-422-71-5381, E-mail: thisamatsu@ks.kyorin-u.ac.jp
Received: January 12, 2017; Revised: March 19, 2017; Accepted: March 20, 2017; Published online: May 22, 2017.
© Korean Association for the Study of Intestinal Diseases. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Behçet’s disease (BD) is a chronic relapsing disease involving multiple organ systems. BD is characterized clinically by oral and genital aphthae, cutaneous lesions, and ophthalmological, neurological, and/or gastrointestinal manifestations. It is widely recognized that the presence of intestinal lesions may be a poor prognostic factor in intestinal BD, increasing the risk of surgery and decreasing the quality of life. Despite this, the management of intestinal BD has not been standardized. Empirical therapies including 5-aminosalicylic acid and corticosteroids have been used anecdotally to treat intestinal BD, but recent studies have provided evidence for the efficacy of anti-tumor necrosis factor α monoclonal antibodies. The development of agents targeting tumor necrosis factor α continues, it seems likely that they will change the therapeutic strategy and clinical outcomes of intestinal BD and inflammatory bowel disease. Monitoring disease activity such as endoscopic evaluation will become more important to obtain better outcomes. Here, we review current and future perspectives in the treatment and outcomes of intestinal BD.
Keywords: Intestinal Behçet’s disease; Anti-TNF-α mAb; Mucosal healing


This Article

e-submission

Archives

Official Journal of

Indexed/Covered by